Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome

MLA

Nicole L Pratt, et al. “Reducing Medicine-Induced Deterioration and Adverse Reactions (ReMInDAR) Trial: Study Protocol for a Randomised Controlled Trial in Residential Aged-Care Facilities Assessing Frailty as the Primary Outcome.” BMJ Open, vol. 10, no. 4, Apr. 2020. EBSCOhost, https://doi.org/10.1136/bmjopen-2019-032851.

APA

Nicole L Pratt, Lisa M Kalisch Ellett, Elizabeth Ellen Roughead, Renly Lim, Megan Corlis, Gaynor Parfitt, Debra Rowett, Luke Bereznicki, Ai Choo Kang, Tracy Merlin, Stacey Torode, Joseph Whitehouse, Andre Q Andrade, Rebecca Bilton, Justin Cousins, Lan Kelly, Camille Schubert, & Mackenzie Williams. (2020). Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome. BMJ Open, 10(4). https://doi.org/10.1136/bmjopen-2019-032851

Chicago

Nicole L Pratt, Lisa M Kalisch Ellett, Elizabeth Ellen Roughead, Renly Lim, Megan Corlis, Gaynor Parfitt, Debra Rowett, et al. 2020. “Reducing Medicine-Induced Deterioration and Adverse Reactions (ReMInDAR) Trial: Study Protocol for a Randomised Controlled Trial in Residential Aged-Care Facilities Assessing Frailty as the Primary Outcome.” BMJ Open 10 (4). doi:10.1136/bmjopen-2019-032851.